GPEx® To Increase Production Of Pritumumab

Summary: Pritumumab has been used in a Phase II setting with brain cancer patients. The original human-human hybridoma secreted approximately 1 picogram of hyridoma per cell per day. The level of the antibody production posed a cost and time concern for late stage clinical trials.

Download the Poster